Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

762 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vector.
Giel-Moloney M, Esteban M, Oakes BH, Vaine M, Asbach B, Wagner R, Mize GJ, Spies AG, McElrath J, Perreau M, Roger T, Ives A, Calandra T, Weiss D, Perdiguero B, Kibler KV, Jacobs B, Ding S, Tomaras GD, Montefiori DC, Ferrari G, Yates NL, Roederer M, Kao SF, Foulds KE, Mayer BT, Bennett C, Gottardo R, Parrington M, Tartaglia J, Phogat S, Pantaleo G, Kleanthous H, Pugachev KV. Giel-Moloney M, et al. Among authors: montefiori dc. Sci Rep. 2019 Dec 27;9(1):20005. doi: 10.1038/s41598-019-56550-4. Sci Rep. 2019. PMID: 31882800 Free PMC article.
Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.
Belshe RB, Gorse GJ, Mulligan MJ, Evans TG, Keefer MC, Excler JL, Duliege AM, Tartaglia J, Cox WI, McNamara J, Hwang KL, Bradney A, Montefiori D, Weinhold KJ. Belshe RB, et al. AIDS. 1998 Dec 24;12(18):2407-15. doi: 10.1097/00002030-199818000-00009. AIDS. 1998. PMID: 9875578 Clinical Trial.
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.
Bures R, Gaitan A, Zhu T, Graziosi C, McGrath KM, Tartaglia J, Caudrelier P, El Habib R, Klein M, Lazzarin A, Stablein DM, Deers M, Corey L, Greenberg ML, Schwartz DH, Montefiori DC. Bures R, et al. Among authors: montefiori dc. AIDS Res Hum Retroviruses. 2000 Dec 10;16(18):2019-35. doi: 10.1089/088922200750054756. AIDS Res Hum Retroviruses. 2000. PMID: 11153085 Clinical Trial.
Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.
Mascola JR, Sambor A, Beaudry K, Santra S, Welcher B, Louder MK, Vancott TC, Huang Y, Chakrabarti BK, Kong WP, Yang ZY, Xu L, Montefiori DC, Nabel GJ, Letvin NL. Mascola JR, et al. Among authors: montefiori dc. J Virol. 2005 Jan;79(2):771-9. doi: 10.1128/JVI.79.2.771-779.2005. J Virol. 2005. PMID: 15613305 Free PMC article.
762 results